{
    "clinical_study": {
        "@rank": "28365", 
        "arm_group": [
            {
                "arm_group_label": "LCB01-0371 800mg", 
                "arm_group_type": "Experimental", 
                "description": "LCB01-0371  800mg"
            }, 
            {
                "arm_group_label": "LCB01-0371 1200mg", 
                "arm_group_type": "Experimental", 
                "description": "LCB01-0371 1200mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary\n\n      - To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose\n\n        -  To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral\n           dose\n\n        -  To investigate the safety of LCB01-0371 after a multiple oral dose"
        }, 
        "brief_title": "Multiple Ascendoing Dose Study for LCB01-0371", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "-  To investigate the PK characteristics of LCB01-0371 after a multiple oral dose\n\n        -  To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Health Male between 20 and 45 years of age at the time of screening and a subject\n             with body mass index (BMI) between 19 and 27\n\n          2. Medically healthy with no clinically significant screening results through Physical\n             examination, x-ray, 12 lead ECG, Laboratory test\n\n          3. Able to donate blood during study period and follow visit.\n\n          4. Agree to continue to use a reliable method of birth control until 60 days after study\n             completion.\n\n          5. Capable of giving written informed consent and Able to understand and comply with\n             protocol requirements, instructions and protocol-stated restrictions.\n\n        Exclusion Criteria:\n\n          1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic,\n             neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).\n\n          2. History of gastrointestinal problem which is affect to absorption within 6 months\n             from screening\n\n          3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the\n             LCB01-0371, same class of the study drugs (linezolid), or other drugs including\n             aspirin and antibiotics.\n\n          4. History drug abuse or positive result of urine drug screening test for amphetamine,\n             methamphetamine, barbiturate, cocaine, opiate, benzodiazepine, cannabinoid,\n             methadone, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842516", 
            "org_study_id": "LCB01-0371-12-1-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "LCB01-0371 800mg", 
                "description": "LCB0-0371 800mg", 
                "intervention_name": "LCB01-0371 800mg", 
                "intervention_type": "Drug", 
                "other_name": "LCB0-0371 800mg"
            }, 
            {
                "arm_group_label": "LCB01-0371 1200mg", 
                "description": "LCB01-0371 1200mg", 
                "intervention_name": "LCB01-0371 1200mg", 
                "intervention_type": "Drug", 
                "other_name": "LCB01-0371 1200mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 24, 2013", 
        "location": {
            "contact": {
                "email": "ksbae@amc.seoul.kr", 
                "last_name": "Kyun-Seop Bae, M.D., Ph.D.", 
                "phone": "82-2-3010-4611"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyun-Seop Bae, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCB01-0371 in Healthy Male Subjects.", 
        "overall_contact": {
            "last_name": "Kyun-Seop Bae, , MD, PhD."
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Kyun-Seop Bae, MD, PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "No", 
            "time_frame": "Up to 7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842516"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of LCB01-0371", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 days"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of LCB01-0371", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 days"
            }
        ], 
        "source": "LegoChem Biosciences, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LegoChem Biosciences, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}